Tieron / Targeting
Annual report 2026-08-28
Companies › Japanese listed company

第一三共株式会社 (DAIICHI SANKYO COMPANY, LIMITED)

Tokyo Stock Exchange 4568, Pharmaceutical. Supply-chain directory entry built from public EDINET filings, including relationships the company disclosed in its own annual securities report.

COMPANY NAME (JP)
第一三共株式会社
TICKER
TSE 4568
EDINET CODE
E00984
CORPORATE NUMBER
1010001095640
INDUSTRY
Pharmaceutical (医薬品)
HEAD OFFICE
中央区日本橋本町三丁目5番1号
DISCLOSED FOOTPRINT
16 sites · 18 subsidiaries

Disclosed major customers

Counterparties DAIICHI SANKYO COMPANY, LIMITED named in its own annual securities report. A third-party company named here has DAIICHI SANKYO COMPANY, LIMITED in its supply base.

マッケソン社12.7% of revenue
マッケソン社 | 前連結会計年度 203,461百万円(10.8%) | 当連結会計年度 269,418百万円(12.7%)
Annual securities report (有価証券報告書), filed 2026-08-28 — EDINET S100YZB3
センコラ社11.8% of revenue
センコラ社 | 前連結会計年度 207,389百万円(11.0%) | 当連結会計年度 251,034百万円(11.8%)
Annual securities report (有価証券報告書), filed 2026-08-28 — EDINET S100YZB3
アルフレッサ ホールディングス株式会社及びそのグループ会社10.9% of revenue
アルフレッサ ホールディングス株式会社及びそのグループ会社 | 前連結会計年度 221,814百万円(11.8%) | 当連結会計年度 232,433百万円(10.9%)
Annual securities report (有価証券報告書), filed 2026-08-28 — EDINET S100YZB3

Disclosed suppliers

Suppliers DAIICHI SANKYO COMPANY, LIMITED named in its own annual securities report.

WITHIN THE GROUP — DAIICHI SANKYO COMPANY, LIMITED’s own consolidated subsidiaries and affiliates (関係会社の状況). Intra-group transfers, not third-party trade.
第一三共バイオテック株式会社
第一三共バイオテック株式会社埼玉県北本市50医薬品100.0役員の兼任等当社が製品を購入当社が研究開発業務を委託当社が事務室を賃貸当社が設備資金を貸与
Annual securities report (有価証券報告書), filed 2026-08-28 — EDINET S100YZB3

Business segments

医薬品事業
100% of revenue医療用医薬品, ヘルスケア, その他
The filing states a human-rights policy and describes human-rights due diligence: “当社グループのリスクマネジメントには、気候変動、人権、環境、サプライチェーン等のサステナビリティに関連するリスクも包括的に含まれております。リスクの識別・評価において、サステナビリティ関連のリスクとその他リスクとの評価方法や優先順位付けの方法に差異はなく、リスク識別の段階から総合的リスク管理の枠組みの中で一体的に管理しております。

Sector risk context: supply-chain risk by country and sector.

More Pharmaceutical companies

Eisai Co., Ltd.Takeda Pharmaceutical Company LimitedAnGes, Inc.ASKA Pharmaceutical Holdings CO., Ltd.BrightPath Biotherapeutics Co., Ltd.CanBas Co.,Ltd.Carna Biosciences, Inc.Chiome Bioscience Inc.
Screening DAIICHI SANKYO COMPANY, LIMITED or mapping suppliers like them? Check any company against sanctions and forced-labor lists, free.Free sanctions check →

Work at DAIICHI SANKYO COMPANY, LIMITED? Claim this page to review the data your customers see.

Get sanctions & UFLPA list updates
A short note when the lists change in ways that matter for supply-chain screening. No noise.
Sources: EDINET code list (Financial Services Agency) and the company’s own annual securities report (有価証券報告書) retrieved via EDINET. Disclosed relationships are quoted from the filing and carry its EDINET accession number; extraction is automated and conservative — anything the filing does not state is left out. Tieron does not certify, audit or endorse the company, and this page contains no Tieron risk assessment. Report an issue with this page — corrections referencing the accession number shown above are fastest to verify.
第一三共株式会社の取引先・主要顧客 — DAIICHI SANKYO COMPANY, LIMITED suppliers & customers · Tieron